| Neurent Medical–Life Sciences Partners: investment, 202101 financing round Series B totalling €21m incl lead investor LSP Health Economics Fund 2 |
2021-01-20 |
| Neurent Medical–SEVERAL: investment, 202101 financing round Series B €21m led by LSP Health Economics Fund 2 |
2021-01-20 |
| CoviCept Therapeutics–Forbion: investment, 202101 seed investment $2.3 from Forbion |
2021-01-19 |
| Novasep–Thermo Fisher: investment, 202101 acquisition €725m in cash of viral vector manufacturing business Henogen SA in Belgium by Thermo Fisher |
2021-01-15 |
| NewAmsterdam Pharma–SEVERAL: investment, 202101 financing round Series A €160m co-led by Morningside Ventures + Ascendant BioCapital |
2021-01-14 |
| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP |
2021-01-11 |
| BioGeneration Ventures–BMS: investment, 202101 final closing of BGV IV totalling €140m incl investor BMS |
2021-01-07 |
| BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund |
2021-01-07 |
| BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital |
2021-01-07 |
| BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension |
2021-01-07 |
| BioGeneration Ventures–Instinctif Partners: public relations, 202101 service existent by Instinctif |
2021-01-07 |
| BioGeneration Ventures–Lilly: investment, 202101 final closing of BGV IV totalling €140m incl investor Eli Lilly |
2021-01-07 |
| BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures |
2021-01-07 |
| BioGeneration Ventures–Schroders: investment, 202101 final closing of BGV IV totalling €140m incl investor Schroder Adveq |
2021-01-07 |
| BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
| Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare |
2021-01-05 |
| Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare |
2021-01-05 |
| Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use |
2021-01-01 |
| Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime |
2020-12-31 |
| Univercells–Farallon Capital: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor Farallon Capital Management |
2020-12-17 |
| Univercells–Korea Investment Partners: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor KIP Bio Global Fund |
2020-12-17 |
| Univercells–SEVERAL: investment, 202012 financing round Series C 2nd closing €20m with Soros EDF + Farallon Capital et al |
2020-12-17 |
| Univercells–Soros Economic Development Fund: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor Soros EDF |
2020-12-17 |
| Univercells–TheClubDeal Fund: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor TheClubDeal Fund |
2020-12-17 |
| Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
| Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund |
2020-11-25 |
| Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG |
2020-11-25 |
| Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund |
2020-11-25 |
| Galapagos–Selvita: drug discovery services, 202011– 202512 supply for 5y by Fidelta after sale by Galapgaos to Selvita |
2020-11-23 |
| Galapagos–Selvita: investment, 202011– acquisition 100% of Fidelta d.o.o. for €31.2m in cash by Selvita SA |
2020-11-23 |
| Achilles Therapeutics–Forbion: investment, 202011 financing round Series C totalling £52.7m incl existing investor Forbion |
2020-11-19 |
| Achilles Therapeutics–SEVERAL: investment, 202011 financing round Series C £52.7m with new + existing investors |
2020-11-19 |
| SynOx Therapeutics–Forbion: investment, 202011 financing round Series A totalling €37m incl co-investor Forbion |
2020-11-19 |
| SynOx Therapeutics–Gimv: investment, 202011 financing round Series A totalling €37m incl co-investor Gimv |
2020-11-19 |
| SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv |
2020-11-19 |
| BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent |
2020-11-18 |
| DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED |
2020-11-18 |
| Pharvaris–Bain Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Bain Capital Life Sciences |
2020-11-18 |
| Pharvaris–Cormorant Asset Management: investment, 202011 financing round Series C totalling $80m incl new + co-investor Cormorant Asset Management |
2020-11-18 |
| Pharvaris–Foresite Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Foresite Capital |
2020-11-18 |
| Pharvaris–General Atlantic: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor General Atlantic |
2020-11-18 |
| Pharvaris–Rockefeller: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Venrock Health Capital Partners |
2020-11-18 |
| Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic |
2020-11-18 |
| Pharvaris–VenBio: investment, 202011 financing round Series C totalling $80m incl existing + co-investor venBio Partners |
2020-11-18 |
| Pharvaris–Viking Global Investors: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor Viking Global Investors |
2020-11-18 |
| Lead Pharma–LifeSpring: public relations, 202011 service existent by LifeSpring Communications |
2020-11-16 |
| Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties |
2020-11-16 |
| Apaxen–LifeSpring: public relations, 202011 service existent by LifeSpring Life Sciences Communications |
2020-11-12 |
| Handl Therapeutics–UCB: investment, 202011 acquisition of Handl Therapeutics by UCB |
2020-11-12 |
| Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III |
2020-11-10 |
| Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III |
2020-11-10 |
| The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings |
2020-11-03 |
| Eurofins–Waters: mass spectrometer, 202011 supply existent Radian ASAP System beta customer Eurofins Forenscis Teddington |
2020-11-02 |
| Fountain Healthcare Partners–Kyowa Kirin: investment, 202011 final closing of Fund III totalling addit €7m incl new investor Kyowa Kirin Co Ltd |
2020-11-02 |
| Fountain Healthcare Partners–SEVERAL: investment, 202011 final closing of Fund III addit €7m incl Kyowa Kirin bringing total fund to hard cap of €125m |
2020-11-02 |
| Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) |
2020-11-02 |
| Unilever–Eagle Genomics: microbiomics, <202010 collab use of e[datascientist] platform to support claims for enzyme-containing Zendium toothpaste |
2020-10-27 |
| Gilead–ProteoNic: rec protein production technology, 202010– licensel €na to use 2G UNic technology to Immunomedics |
2020-10-20 |
| ProteoNic–LifeSpring: public relations, 202010 service existent by LifeSpring Life Sciences Communications |
2020-10-20 |
| Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners |
2020-10-19 |
| Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF |
2020-10-19 |
| Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv |
2020-10-19 |
| Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors |
2020-10-19 |
| Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III |
2020-10-19 |
| Oncopeptides–EU (govt): credit, 202010– unsecured €40m loan facility in three tranches with each 5y maturity from EIB |
2020-10-14 |
| Neogene Therapeutics–Twist Bioscience: cell therapy, 202010– collab strategic partnership using DNA synthesis platform to develop T cell therapies |
2020-10-13 |
| Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis |
2020-10-06 |
| Ynsect–SEVERAL: investment, 202010 financing round Series C extension to total of $372m led by Astanor Ventures |
2020-10-06 |
| Sophia Genetics–Alychlo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Alychlo |
2020-10-01 |
| Mosa Meat–Bell Food: investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor Bell Food Group |
2020-09-25 |
| Mosa Meat–Blue Horizon Ventures: investment, 202009 financing round Series B 1st closing totalling $55m incl new + lead investor Blue Horizon Ventures |
2020-09-25 |
| Mosa Meat–Merck (DE): investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor M Ventures |
2020-09-25 |
| Mosa Meat–SEVERAL: investment, 202009 financing round Series B 1st closing $55m led by Blue Horizon Ventures |
2020-09-25 |
| AM-Pharma–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP |
2020-09-23 |
| Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund |
2020-09-23 |
| Salvia BioElectronics–ABP (NL): investment, 202009 financing round Series A totalling €21m incl new + co-lead investor Inkef Capital |
2020-09-22 |
| Salvia BioElectronics–Dolby Family Ventures: investment, 202009 financing round Series A totalling €21m incl co-investor Dolby Family Ventures |
2020-09-22 |
| Salvia BioElectronics–Netherlands (govt): credit, 202009 deferred risk-bearing Innovation Credit €5m from RVO |
2020-09-22 |
| Salvia BioElectronics–Netherlands (govt): investment, 202009 financing round Series A totalling €21m incl co-investor BOM Brabant Ventures |
2020-09-22 |
| Salvia BioElectronics–Panakès Partners: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor Panakès Partners |
2020-09-22 |
| Salvia BioElectronics–SEVERAL: investment, 202009 financing round Series A €21m co-led by Panakès Partners + Inkef Capital + SHS |
2020-09-22 |
| Salvia BioElectronics–SHS: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor SHS |
2020-09-22 |
| Salvia BioElectronics–Thuja Capital: investment, 202009 financing round Series A totalling €21m incl co-investor Thuja Capital |
2020-09-22 |
| Sundew–Novo Group: investment, 202009 seed financing round totalling €1.4m inkl DKK10m (€1.34m) from Novo Nordisk BII |
2020-09-22 |
| Sundew–SEVERAL: investment, 202009 seed financing round €1.4m with €1.34m from Novo Nordisk BII + €85k from StartLife |
2020-09-22 |
| Sundew–StartLife (NL): investment, 202009 seed financing round totalling €1.4m inkl €85k from StartLife |
2020-09-22 |
| Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures |
2020-09-17 |
| Lava Therapeutics–Gilde Investment: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Gilde Healthcare |
2020-09-17 |
| Lava Therapeutics–Merck (US): investment, 202009 financing round Series C totalling $83m incl existing + co-investor MRL Ventures Fund LLC |
2020-09-17 |
| Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures |
2020-09-17 |
| Lava Therapeutics–Redmile Group: investment, 202009 financing round Series C totalling $83m incl new + co-investor Redmile Biopharma Investments |
2020-09-17 |
| Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures |
2020-09-17 |
| Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
| Lava Therapeutics–Versant Ventures: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Versant |
2020-09-17 |
| Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital |
2020-09-17 |
| Neogene Therapeutics–EcoR1 Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor EcorR1 Capital |
2020-09-14 |
| Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital |
2020-09-14 |
| Neogene Therapeutics–Polaris Partners: investment, 202009 financing round Series A totalling $110m incl new + co-investor Polaris Partners |
2020-09-14 |
| Neogene Therapeutics–Pontifax: investment, 202009 financing round Series A totalling $110m incl new + co-investor Pontifax |
2020-09-14 |
![[LSBNL] Life-Sciences-Benelux.com - The Benelux Life Sciences Web Portal](/images/basics/lsbnl-life-sciences-benelux-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] Made Without Love 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-made-without-love.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
